Benjamin Halladay

Ben Halladay is the Chief Financial Officer at AchieveRx and has spent more than 15 years of financial management experience across commercial and launch environments. Before joining AchieveRx Ben served as the Chief Financial Officer of Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue. During his tenure, Esperion deleveraged its balance sheet and acquired Corstasis Therapeutics and its product Enbumyst. He led the finance workstream through the company’s sale to ARCHIMED for up to $1.1 billion. Earlier, Ben held positions at Pfizer Inc., where he worked on Lipitor and Chantix in the Primary Care business unit, and at National Oilwell Varco, a Fortune 500 global industrial company. He holds an MBA from Fordham University and a BA from Syracuse University and is a Certified Public Accountant (inactive).